Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Evolutionary Adaptation of Pseudomonas aeruginosa in Response to CFTR Modulator Therapy in individuals with Cystic Fibrosis

Award Number: F32AI200229
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 11/19/2026
PERIOD OF PERFORMANCE END DATE: 11/18/2027

Group Awards By:

View Award Description

Evolutionary Adaptation of Pseudomonas aeruginosa in Response to CFTR Modulator Therapy in individuals with Cystic Fibrosis - Project Summary Cystic fibrosis (CF) is a genetic disorder that results in thick mucus accumulation in the lungs, leading to chronic infections and progressive respiratory decline. Pseudomonas aeruginosa (Pa) is an important pathogen in the CF lung, establishing chronic infections starting with a single infecting strain and evolving into diverse populations that lead to a deterioration of lung function. The advent of highly effective CFTR modulator therapies (HEMT), particularly Elexacaftor/Tezacaftor/Ivacaftor (Trikafta), has transformed clinical outcomes for people with CF (pwCF) by improving lung function and reducing bacterial load. However, many pwCF with chronic Pa infections do not completely clear the pathogen despite clinical improvements, and in some cases, Pa load increases after one year of therapy. The mechanisms by which Pa adapts to this new lung environment remain poorly understood, representing a major gap in our understanding of pathogen evolution under HEMT-induced niche shifts. This proposal investigates the evolutionary dynamics of heterogeneous Pa populations in response to Trikafta treatment in pwCF with chronic lung infections. My overarching hypothesis is that modulator therapy drastically changes the niches available to Pa in the lungs of pwCF leading to diverse pathoadaptive evolutionary strategies. To address this, I propose two aims: (1) characterize the genetic diversity of Pa populations isolated from pwCF on Trikafta and compare them to pre-treatment populations, and (2) assess how Trikafta influences pathoadaptive traits and antimicrobial resistance and tolerance in these populations. I will build on a previously established biobank of Pa isolates from four chronically infected individuals prior to starting Trikafta, collect matched post-treatment sputum samples, and culture and sequence 75 isolates per individual. These isolates will be assessed for genomic diversity, presence of hypermutators, and resistance genes using short- and long- read sequencing platforms and bioinformatics pipelines. I will then evaluate antimicrobial susceptibility, aggregate formation, alginate production, motility, and cell surface hydrophobicity to characterize functional adaptations associated with treatment. The innovative approach of deep isolate-level analysis across matched timepoints enables insight into both within-host evolution and population-level heterogeneity. This project will also generate a valuable biobank of 300 post-Trikafta Pa isolates to complement the existing pre-treatment collection. Findings from this work will improve our understanding of persistent Pa infections in the modulator era and provide insight into the evolutionary trajectory of Pa in the modulator era. The research and training in this proposal will equip me with advanced skills in genomics, phenotypic analysis, and CF microbiology, supporting my long-term goal of becoming an independent investigator studying microbial evolution in chronic lung infections.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $79,348 )
2026	2026	GEORGIA TECH RESEARCH CORP	926 DALNEY ST NW	ATLANTA	GA	30318	FULTON	USA	Allergy and Infectious Diseases Research	000	1	5/20/2026	NEW	$79,348
														Subtotal = $79,348

Grand Total All Awards = $79,348

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Evolutionary Adaptation of Pseudomonas aeruginosa in Response to CFTR Modulator Therapy in individuals with Cystic Fibrosis

Award Number: F32AI200229

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 11/19/2026

PERIOD OF PERFORMANCE END DATE: 11/18/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer